Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Pregabalin 75mg capsules: MHRA batch alert
- CQC annual report: safer management of controlled drugs
- Care of the dying: NICE guideline consultation
- Legislation changes for the availability of parenteral naloxone
- MHRA further measures to minimise risk of ONJ with denosumab and IV bisphosphonates
- Cochrane review: Antidepressants for the treatment of depression in people with cancer
- Ketamine 50mg/mL injection back in stock
- Phenobarbital 200mg/mL injection shortage
- Co-danthramer and strong co-danthramer capsules discontinued
- Ketamine supply update